Tarah J. Ballinger, MD, conveys the immediate impact that the results from the DESTINY-Breast04 trial will have on her patients with triple-negative and hormone-refractory metastatic breast cancer.
The results of the trial lead Dr Ballinger to think about a specific patient who is now classified as having HER2-low disease, thus allowing her to tap the potential for better quality of life with the option of trastuzumab deruxtecan.
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: ASCO 2022: Immediate Options for Endocrine Therapy–Refractory Patients With HER2-Low Metastatic Breast Cancer - Medscape - Jun 23, 2022.
Comments